The global demand for weight management drugs, particularly Ozempic and Wegovy, has surged due to the rising obesity crisis, with projections estimating the obesity drug market could reach $100 billion by 2030. These drugs, which share the same active ingredient, semaglutide, have gained popularity not only for their effectiveness in managing diabetes but also for their appetite-suppressing effects, leading to significant sales and global shortages. Novo Nordisk, the manufacturer, has become Europe's most valuable company, reflecting the immense market potential. In cultural events, the House of Oz recently showcased Australian talent at the Edinburgh Fringe, emphasizing the importance of artistic expression and indigenous acknowledgment. The evening featured a variety of performances, highlighting the connection between art and community. Amidst these developments, Ozempic remains a focal point in both healthcare and popular culture.